Your browser is no longer supported. Please, upgrade your browser.
TPTX Turning Point Therapeutics, Inc. daily Stock Chart
Turning Point Therapeutics, Inc.
Index- P/E- EPS (ttm)-9.88 Insider Own8.00% Shs Outstand31.33M Perf Week16.44%
Market Cap1.64B Forward P/E- EPS next Y-2.89 Insider Trans- Shs Float26.85M Perf Month33.44%
Income- PEG- EPS next Q-0.56 Inst Own57.80% Short Float5.79% Perf Quarter35.20%
Sales- P/S- EPS this Y-49.40% Inst Trans- Short Ratio9.07 Perf Half Y-
Book/sh8.36 P/B6.25 EPS next Y30.00% ROA- Target Price52.20 Perf Year-
Cash/sh2.52 P/C20.79 EPS next 5Y- ROE- 52W Range24.21 - 53.00 Perf YTD80.90%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-0.48% Beta-
Dividend %- Quick Ratio32.30 Sales past 5Y- Gross Margin- 52W Low117.86% ATR3.22
Employees77 Current Ratio32.30 Sales Q/Q- Oper. Margin- RSI (14)71.57 Volatility10.75% 7.61%
OptionableNo Debt/Eq0.00 EPS Q/Q- Profit Margin- Rel Volume2.02 Prev Close52.28
ShortableYes LT Debt/Eq0.00 EarningsAug 06 AMC Payout- Avg Volume171.37K Price52.74
Recom1.20 SMA2025.69% SMA5026.57% SMA20037.63% Volume36,738 Change0.89%
Jul-24-19Initiated Guggenheim Buy $58
May-13-19Initiated Wells Fargo Outperform
May-13-19Initiated SVB Leerink Outperform $42
May-13-19Initiated RBC Capital Mkts Outperform $48
May-13-19Initiated Goldman Buy $50
Aug-06-19 04:05PM  Turning Point Therapeutics Reports Second Quarter 2019 Financial and Operational Results GlobeNewswire
Aug-01-19 02:31PM  What Kind Of Shareholder Appears On The Turning Point Therapeutics, Inc.'s (NASDAQ:TPTX) Shareholder Register? Simply Wall St.
Jul-31-19 04:30PM  Turning Point Therapeutics CEO to Present at Canaccord Genuity 39th Annual Growth Conference GlobeNewswire
08:30AM  Turning Point Therapeutics Initiates Phase 1 Clinical Study of Tpx-0022, a Novel Met Inhibitor Targeting Advanced Solid Tumors GlobeNewswire
Jul-29-19 08:30AM  Turning Point Therapeutics Appoints Biotechnology Investment Banker Yi Larson as Executive Vice President and Chief Financial Officer GlobeNewswire
Jul-25-19 08:30AM  Turning Point Therapeutics Names Carol Gallagher, Pharm.D. to its Board of Directors GlobeNewswire
Jul-22-19 09:00AM  Turning Point Therapeutics to Host Second Quarter 2019 Conference Call GlobeNewswire
Jun-20-19 09:00AM  Turning Point Therapeutics Initiates Phase 2 Registrational Portion of TRIDENT-1 Clinical Study GlobeNewswire
Jun-18-19 07:09AM  Shares of cancer-therapy companies skyrocket after Pfizer acquisition news MarketWatch
Jun-04-19 08:30AM  Turning Point Therapeutics CEO to Present at Goldman Sachs 40th Annual Global Healthcare Conference GlobeNewswire
May-31-19 08:30AM  Turning Point Therapeutics Announces Updated Interim Clinical Data of Repotrectinib in Advanced ROS1+ Non-Small Cell Lung Cancer GlobeNewswire -10.26%
May-24-19 09:36AM  Bay Area figures prominently in hottest IPOs so far this year American City Business Journals
May-15-19 09:00AM  Turning Point Therapeutics Announces FDA Clearance of Investigational New Drug Application for TPX-0022, a Novel MET/CSF1R/SRC Inhibitor GlobeNewswire
May-14-19 04:30PM  Turning Point Therapeutics' CEO to Present at UBS Healthcare Conference GlobeNewswire
09:00AM  Turning Point Therapeutics Names Biotech Veteran Patrick Machado, J.D. to Its Board of Directors GlobeNewswire
May-06-19 09:00AM  Turning Point Therapeutics and Almac Diagnostic Services Announce Approval of an Investigational Device Exemption for the Companion Diagnostic Assay to the Registrational TRIDENT-1 Clinical Study GlobeNewswire
Apr-29-19 12:57PM  Weekly CEO Buys Highlight +5.69%
Apr-24-19 08:15PM  Turning Point Therapeutics Inc (TPTX) President & CEO Athena Countouriotis Bought $216,000 ...
Apr-22-19 04:05PM  Turning Point Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares GlobeNewswire
Apr-17-19 11:01AM  Turning Point Therapeutics IPO: What You Need To Know Benzinga
Apr-16-19 10:57PM  Turning Point Therapeutics Announces Pricing of Initial Public Offering Business Wire
Apr-14-19 09:53AM  IPO Outlook For The Week: Pinterest, Zoom, Biotechs, Minerals And Catastrophe Insurance Benzinga
Turning Point Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in designing and developing novel small molecule targeted oncology therapies. It develops a pipeline of tyrosine kinase inhibitors (TKIs) that targets genetic drivers of cancer in TKI-naive and TKI-pretreated patients. The company's lead drug candidate repotrectinib (TPX-0005) is being evaluated in an ongoing Phase 1/2 trial called TRIDENT-1 for the treatment of patients with ROS1+ advanced non-small-cell lung cancer (NSCLC) and patients with ROS1+, NTRK+ or ALK+ advanced solid tumors. Its pipeline also includes multi-targeted drug candidates TPX-0046, a RET/SRC inhibitor; TPX-0022, a MET/CSF1R/SRC inhibitor; and a series of ALK inhibitors. The company was incorporated in 2013 and is headquartered in San Diego, California.